TauRx Pharmaceuticals Ltd - Company & Market Research Reports

TauRx Pharmaceuticals Ltd. discovers and develops treatments and diagnostics for Alzheimer's disease and other neurodegenerative diseases. The company's best known product, LMTX, inhibits aggregation of tau, synuclein, TPD-43 and huntingtin proteins. The LMTX Phase 3 clinical trial programme, conducted in over 20 countries and involving over 1,900 patients, has recently completed. TauRx Pharmaceuticals Ltd. was founded in 2002 and is based in Singapore with a research facility in Aberdeen, Scotland.

Attention Deficit Hyperactivity Disorder (ADHD): Market Intelligence Review and Insights - Product Thumbnail Image

Attention Deficit Hyperactivity Disorder (ADHD): Market Intelligence Review and Insights

  • Report
  • 50 Pages
From
Progressive Supranuclear Palsy (PSP) Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments. - Product Thumbnail Image

Progressive Supranuclear Palsy (PSP) Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.

  • Report
  • 80 Pages
From
Alzheimer s: Epidemiology Overview and Insights - Product Thumbnail Image

Alzheimer s: Epidemiology Overview and Insights

  • Report
  • 50 Pages
From
Alzheimer's: Disease Inights and Market Forecasts to 2024 - Product Thumbnail Image

Alzheimer's: Disease Inights and Market Forecasts to 2024

  • Report
  • 120 Pages
From
Alzheimer'S Disease: Pharmacuetical Drugs Vs. Medicinal Plants - Markets, Competitors and Opportunities: 2015-2020 Analysis and Forecasts - Product Thumbnail Image

Alzheimer'S Disease: Pharmacuetical Drugs Vs. Medicinal Plants - Markets, Competitors and Opportunities: 2015-2020 Analysis and Forecasts

  • Report
  • 77 Pages
From
Alzheimer's Disease Therapeutics and Diagnostics: Global Markets - Product Thumbnail Image

Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

  • Report
  • 144 Pages
From
Alzheimer's Drugs Market, 2012 - 2017 - Product Thumbnail Image

Alzheimer's Drugs Market, 2012 - 2017

  • Report
  • 117 Pages
From
Alzheimer's Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies - Product Thumbnail Image

Alzheimer's Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies

  • Report
  • 151 Pages
From
Alzheimer's Disease Therapeutics in Major Developed Markets to 2021 - Aging Population and Improved Disease Understanding Increase Demand for Disease Modifying Agents - Product Thumbnail Image

Alzheimer's Disease Therapeutics in Major Developed Markets to 2021 - Aging Population and Improved Disease Understanding Increase Demand for Disease Modifying Agents

  • Report
  • 144 Pages
From
Parkinson's Disease Market: Pipeline Review, Developer Landscape and Competitive Insights - Product Thumbnail Image

Parkinson's Disease Market: Pipeline Review, Developer Landscape and Competitive Insights

  • Report
  • 204 Pages
From
Progressive Supranuclear Palsy Global Clinical Trials Review, H1, 2018 - Product Thumbnail Image

Progressive Supranuclear Palsy Global Clinical Trials Review, H1, 2018

  • Clinical Trials
  • 56 Pages
From
Alzheimer's Disease: Competitive Landscape to 2026 - Product Thumbnail Image

Alzheimer's Disease: Competitive Landscape to 2026

  • Report
  • 49 Pages
From
Tau Inhibitor -Pipeline Insight, 2018 - Product Thumbnail Image

Tau Inhibitor -Pipeline Insight, 2018

  • Drug Pipelines
  • 60 Pages
From
Alzheimer's Pipeline Drugs Review, Alzheimer's Disease Drug Market & Forecast – Global Analysis - Product Thumbnail Image

Alzheimer's Pipeline Drugs Review, Alzheimer's Disease Drug Market & Forecast – Global Analysis

  • Report
  • 110 Pages
From
Dementia - Pipeline Review, H1 2018 - Product Thumbnail Image

Dementia - Pipeline Review, H1 2018

  • Drug Pipelines
  • 260 Pages
From
TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Pipeline Review, H2 2016 - Product Thumbnail Image

TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Pipeline Review, H2 2016

  • Drug Pipelines
  • 48 Pages
From
Progressive Supranuclear Palsy- Pipeline Insight, 2018 - Product Thumbnail Image

Progressive Supranuclear Palsy- Pipeline Insight, 2018

  • Drug Pipelines
  • 98 Pages
From
TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016 - Product Thumbnail Image

TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016

  • Drug Pipelines
  • 46 Pages
From
Cognitive Impairment Disorders Drug Development Pipeline Review, 2018 - Product Thumbnail Image

Cognitive Impairment Disorders Drug Development Pipeline Review, 2018

  • Report
  • 376 Pages
From
COPD: Pipeline Assessment and Insights - Product Thumbnail Image

COPD: Pipeline Assessment and Insights

  • Report
  • 100 Pages
From
Loading Indicator
adroll